Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 13,431 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Graft Versus Host Disease Clear all
Recruiting Phase 2 Interventional

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain

NCT07641517
View directory record Official record
Conditions
Osteoarthritis, Knee, Chronic Pain
Interventions
LY4065967, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palm Springs, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Terminated Not applicable Interventional

Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation

NCT00357591
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Continuous Aortic Flow Augmentation
Device
Lead sponsor
Orqis Medical Corporation
Industry
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2009 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Not applicable Interventional

Resilience Coaching for Adolescents With Chronic Musculoskeletal Pain

NCT05834725
View directory record Official record
Conditions
Pain, Chronic, Pain Syndrome, Psychological
Interventions
Promoting Resilience in Stress Management, Usual Care
Behavioral · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional

Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer

NCT00004189
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, becatecarin, cisplatin
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
3
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 6, 2026, 1:09 PM EDT
Terminated Phase 3 Interventional

Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis

NCT03710291
View directory record Official record
Conditions
Metabolic Acidosis, Chronic Kidney Disease
Interventions
TRC101, Placebo
Drug
Lead sponsor
Tricida, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
20
States / cities
Azusa, California • Denver, Colorado • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

NCT00300274
View directory record Official record
Conditions
Graft Rejection
Interventions
everolimus, mycophenolate mofetil, cyclosporine, corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Oct 6, 2026, 1:09 PM EDT
Completed No phase listed Observational

Validating Pain Scales in Children and Young Adults

NCT01639950
View directory record Official record
Conditions
Sickle Cell Disease, Solid Tumor, Leukemia, Neurofibromatosis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 6, 2026, 1:09 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

NCT02970318
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Acalabrutinib (ACP-196), Rituximab, Idelalisib, Bendamustine
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
13
States / cities
Chandler, Arizona • Oxnard, California • Athens, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Recruiting Not applicable Interventional

Pain and Major Depressive Disorder

NCT04556890
View directory record Official record
Conditions
Major Depressive Disorder, Chronic Pain
Interventions
Active rTMS/Active iTBS DFPLC/Sham Pain M1, Active rTMS/Active iTBS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Not applicable Interventional

Music Therapy and Dialysis: A Pilot Investigation Into the Effectiveness of Patient-Selected Music Interventions on Physiological, Psychological, and Quality-of-Life Outcomes

NCT03925168
View directory record Official record
Conditions
End Stage Renal Disease, Depression, Anxiety, Major Depressive Disorder, Generalized Anxiety Disorder, Compliance, Patient, Compliance, Medication, Mood, Pain, Energy Supply; Deficiency, Quality of Life, Blood Pressure, Heart Rate Fast
Interventions
Music therapy
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
New Orleans, Louisiana • Terrytown, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 4 Interventional Results available

Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis

NCT01825408
View directory record Official record
Conditions
Sinusitis
Interventions
Doxycycline, Azithromycin, Augmentin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 6, 2026, 1:09 PM EDT
Not listed Phase 1Phase 2 Interventional

Electrical Acupuncture and Laser Therapy for Low Back Pain

NCT00779818
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Electrical acupuncture, Laser
Device
Lead sponsor
Logan College of Chiropractic
Other
Eligibility
20 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 24, 2008 · Synced Oct 6, 2026, 1:09 PM EDT
Recruiting Not applicable Interventional

Stimulation of the Larynx to Treat Unexplained Chronic Cough

NCT05273190
View directory record Official record
Conditions
Cough
Interventions
Vibrotactile Stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 88 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Active, not recruiting Not applicable Interventional

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

NCT05198674
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions
Renal Denervation (Symplicity Spyral™)
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
1,899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
76
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

NCT05233618
View directory record Official record
Conditions
Myelofibrosis, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions
Tagraxofusp
Drug
Lead sponsor
Karen Ballen, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional

Melphalan in Patients With Neoplastic Meningitis

NCT00002750
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Leukemia, Lymphoma, Ovarian Cancer
Interventions
melphalan
Drug
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 2 Interventional

T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia

NCT00002718
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, filgrastim, cyclophosphamide, cytarabine, methylprednisolone, thiotepa, in vitro-treated bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 49 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 6, 2026, 1:09 PM EDT
Terminated No phase listed Observational

Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)

NCT05915897
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Specimen Donation
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

NCT02296918
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia
Interventions
acalabrutinib, Obinutuzumab, Venetoclax, Rituximab
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 6, 2026, 1:09 PM EDT
Recruiting Not applicable Interventional

Accelerated Age-related Cognitive Decline: Impact of Exercise on Executive Function and Neuroplasticity

NCT05655325
View directory record Official record
Conditions
Mild Cognitive Impairment, Chronic Kidney Diseases
Interventions
Home-based walking exercise, Attention control
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
55 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Terminated Not applicable Interventional Results available

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

NCT01598025
View directory record Official record
Conditions
Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Non-Hodgkins Lymphoma
Interventions
total-body irradiation (TBI), thiotepa, fludarabine phosphate, melphalan, anti-thymocyte globulin, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis
Radiation · Drug · Biological + 2 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 19 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 6, 2026, 1:09 PM EDT
Recruiting Not applicable Interventional

Health Care Transition Readiness Short-Form Video Intervention

NCT06842576
View directory record Official record
Conditions
Health Care Transition Readiness, Health Literacy, Self Efficacy, Emotional Wellbeing, Appointment Attendance
Interventions
Health Education Videos, GotTransition.org Website
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
12 Years to 17 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Treatment for Patients With Chronic Post-Concussion Symptoms

NCT03759808
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Concussion Post Syndrome
Interventions
Psychological Intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 6, 2026, 1:09 PM EDT
Terminated Phase 1 Interventional

Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy

NCT00108108
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
HCD122
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
La Jolla, California • Beech Grove, Indiana • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 6, 2026, 1:09 PM EDT